- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Kevzara® | REGN88 | SAR153191
sarilumab is an approved drug (EMA & FDA (2017))
Compound class: Antibody
Comment: Sarilumab is a monoclonal antibody directed against the interleukin 6 receptor (IL6R).
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Peptide sequence BLAST search using the heavy and light chain variable regions of sarilumab provides 100% matches to sequences covered by patent US7582298 , and to the antibody with designation VQ8F11-21.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|In clinical trial sarilumab significantly reduced the signs and symptoms of RA and improved physical function [1-2,4]. A notable side-effect is immune suppression leading to susceptibility to infection.|
|FDA approved therapeutic for RA (May 2017).|
||Clinical trial in ankylosing spondylitis was terminated.|
||Completed Phase 2 clinical trial for non-infectious uveitis (see NCT01900431).|